or nonlipid actions of HDL, 10, 11 which might be more directly relevant to ASCVD risk. 12, 13 Broader approaches are needed to evaluate the complexities of HDL and its role in ASCVD.
HDL Subfractions and Functionality
Plasma HDL-C concentration integrates cholesterol associated with HDL particles of varying composition, sizes, and function. HDL subfractions follow a stepwise size expansion and contraction, in which they enter circulation as small discs that progressively increase in size and roundedness through reverse cholesterol transport. 8 However, results from a study by Mendivil et al 14 were inconsistent with this model. Using stable isotopic labeling and kinetic modeling, they followed apo (apolipoprotein) AI metabolism in adults with either low or high levels of HDL-C. 14 They demonstrated that each subfraction entered the circulation and remained constant in size for up to 4 days; the stepwise size expansion and contraction model was a minor pathway. 14 This complicates the model of the human HDL lifecycle.
In 126 individuals with a history of ASCVD, Ronsein et al 15 showed that atorvastatin plus niacin raised total HDL particle concentration by 14%; the concentration of medium and large HDL particles increased, whereas small particles decreased. Kempen et al 16 gave MDCO-216 (apo-A1 Milano/ palmitoyl-oleoyl-phosphatidylcholine) infusions to 24 individuals with stable coronary artery disease (CAD) and 24 controls: apo AI levels increased in pre-β1, α-1, and α-2 HDL particles but decreased in α-3 and α-4 HDL particles. The combination of atorvastatin and niacin led to a 16% increase in macrophage cholesterol efflux but did not alter efflux via ABCA1 (ATP-binding cassette transporter A1). 15 Conversely, MDCO-216 increased ABCA1-mediated cholesterol efflux, which correlated with pre-β1 and α-1 HDL levels. 16 In another study, El Khoury et al 17 treated 10 dyslipidemic patients with extended-release niacin/laropiprant and observed an increase in CEC via ABCG1 (ATP-binding cassette transporter A1) and SR-BI (scavenger receptor class B type 1) but a decrease via ABCA1. These studies demonstrate the divergent impact of various drugs on efflux readouts.
Koekemoer et al 18 studied the relationship of CEC with a wide spectrum of metabolic variables. Levels of phospholipids, triglycerides, and Lp(a) [lipoprotein (a)] were all positively correlated to efflux capacity 18 ; after adjusting for levels of HDL-C, clinical determinants of CEC included age, systolic blood pressure, and alcohol consumption. 18 Interestingly, type 2 diabetes mellitus was not a determinant of CEC, which contrasts with a report by Apro et al 19 that showed that the CEC of HDL from interstitial fluid was drastically lower in patients with type 2 diabetes mellitus compared with controls. Koekemoer et al 18 also found a borderline association between CEC and a single-nucleotide polymorphism (SNP) at the ANGPTL8 locus.
Plasma lipids have a complex relationship with the epigenome. 20, 21 The REGICOR study (Registre Gironí del COR) found 5 methylation sites associated with CEC and 1 site associated with HDL inflammatory index. 22 Environmental determinants of CEC are less well characterized, although Bell et al 23 observed that air pollution had negative effects on HDL metrics-including both cholesterol levels and particle number-in 6654 men and women from the MESA (MultiEthnic Study of Atherosclerosis). In 227 patients with familial hypercholesterolemia (FH), Ogura et al 24 found that low CEC was associated with corneal arcus, increased Achilles tendon thickness, and increased carotid intima-media thickness. Lin et al 25 showed in 86 adults without diabetes mellitus, using cholesterol labeling, that intima-media thickness was negatively ABCA1 is central to reverse cholesterol transport; its transcription is regulated by LXRs (liver X receptors) in response to intracellular cholesterol. 26 Nelson et al 27 analyzed the transcriptome of macrophages for LXR ligands and identified EEPD1, encoding EEPD1 (endonuclease/exonuclease/phosphatase family domain containing 1), as an LXR-regulated gene. Further, they proposed that EEPD1 governed cholesterol efflux through posttranscriptional regulation on ABCA1, to assist in the control of its cellular and activity levels. ABCA1 levels are also maintained through internalization and degradation. Mukhamedova et al 28 demonstrated the importance of ARF6 (ADP-ribosylation factor 6) in the fate of ABCA1 internalization in murine macrophages: the ARF6-dependent pathway led to degradation, although the ARF6-independent pathway recycled ABCA1 back to the cell surface, contributing toward efflux of intracellular cholesterol. A study by Yakushiji et al 29 established that spiroquinone and diphenoquinone-oxidized products of probucol-inhibit ABCA1 degradation, thereby increasing levels of HDL-C. Some studies have focused closely on ABCA1 protein interactions. For example, Katsube et al 30 showed that the long form of Pim-1L (serine/threonine-protein kinase Pim-1) phosphorylates cell surface-resident ABCA1, preventing its lysosomal degradation in human hepatocytes. Given this relationship, when levels of Pim-1L were decreased, both ABCA1 and cholesterol efflux to apo AI were decreased.
ABCG1 is another mediator of cholesterol efflux. 31 Gu et al 32 reported that murine ABCG1 with a leucine at position 550, or human ABCG1 with a leucine at position 562, localized to the plasma membrane, whereas a proline at these positions led to intracellular localization. Despite these differences, there was no change in ABCG1-mediated cholesterol efflux. Conflicting results were presented by Tarling and Edwards, 33 who established that regardless of whether there was a proline or a leucine at position 550 of murine ABCG1, consistent localization to intracellular endosomal vesicles was observed, and there was no difference in efflux activity or induction of SREBP (sterol regulatory element-binding protein)-2. Beyond possible differences in protocol, the conflicting results between studies remain unexplained.
ABCA1 and ABCG1 mediate cholesterol efflux to apo AI and HDL, respectively, from both macrophages and endothelial cells (ECs). EC dysfunction is often seen in early atherogenesis, in conjunction with elevated cholesterol levels and abnormal blood flow. [34] [35] [36] [37] Westerterp et al 38 evaluated whether EC efflux could impact atherogenesis. Mice with an EC deficiency of either ABCA1 or ABCG1 on a Western diet showed increased atherosclerotic lesions in the aortic root and whole aorta; in mice with an EC deficiency of both ABCA1 and ABCG1, aortic lesions were further enhanced. 38 Westerterp et al 38 concluded that EC efflux has an important antiatherogenic role, reducing endothelial inflammation by maintaining eNOS (endothelial NO synthase) activity. These results demonstrate the importance of efflux via ABCA1 and ABCG1, which can have nonredundant roles between cell types, including reverse cholesterol transport and inflammation regulation.
ABCA8 colocalizes with ABCA1 and was only recently implicated in cholesterol efflux. Trigueros-Motos et al 39 identified ABCA8 variants predicted to be deleterious in individuals with low HDL-C. Moving into a functional model, Abca8b −/− mice fed a high-cholesterol diet had significantly lower HDL-C compared with wild type. The authors also overexpressed human ABCA8 in mice, leading to a significant increase in HDL-C; however, the wild-type mice in this experiment showed a significant increase in cholesterol efflux to apo AI in vitro. Although additional studies are needed to fully characterize this transporter, it serves as an important reminder about the complexity of cholesterol efflux and HDL functionality. 4, 40, 41 
HDL Components
Apo AI plays key structural and functional roles. 42 It is present for the entirety of reverse cholesterol transport: it is the initial cholesterol acceptor for ABCA1-mediated macrophage efflux and remains until SR-B1 removes cholesterol from the HDL particle, leaving apo AI to restart the cycle. 43, 44 Increased apo AI promotes reverse cholesterol transport and decreases macrophage cholesterol burden. As such, apo AI mimetic peptides are of therapeutic interest for patients with atherosclerosis. 3, 45 Ditiatkovski et al 46 studied 7 different apo AI mimetics in a mouse model of atherosclerosis and found that although they reduced atherosclerosis indices both in vitro and in vivo, in vitro antiatherosclerotic processes were less apparent in vivo. This suggested additional in vitro antiatherosclerotic properties of the peptides. Thus, mechanisms and efficacy cannot be taken for granted when switching between model systems.
Membrane microdomains are important for HDL biogenesis and signaling. [47] [48] [49] Jin et al 47 studied the apo AI mimetic, 5A, in vitro to assess its impact on the mobilization of cholesterol microdomains stored within the extracellular matrix. They found that macrophage-specific ABCA1 was needed for apo AI and the mimetic peptide to take up cholesterol. Interestingly, they also found that when complexed with sphingomyelin, the 5A mimetic could mobilize the cholesterol microdomain independent of ABCA1. 47 Given the results from Ditiatkovski et al, 46 a follow-up to the work of Jin et al 47 could determine the in vivo relevance of these interactions.
There is also keen interest in physiological regulators of apo AI. 42, 48 Liu et al 49 studied liver-specific InsR (insulin receptor) knockout mice and saw reductions in both serum levels of apo AI and hepatic Apoa1 expression. They also noted a 90% reduction in the expression of Dio1, encoding type 1 deiodinase, and showed that Dio1 regulates Apoa1 expression via its promoter both in vivo and in vitro. Beyond transcriptional regulation, they also observed that reduced Dio1 expression led to reduced hepatic synthesis and secretion of apo AI. 49 This novel, interesting mechanism for regulation provides insight into the relationship between insulin signaling, apo AI, and by association, HDL.
HDL has several other constituents, 5 whose role and fate during reverse cholesterol transport have been less well studied. In C57BL/6J mice, Xu et al 50 found that free cholesterol in nascent HDL and phospholipids are rapidly taken up by hepatic SR-B1 but also undergo spontaneous transfer. The study also focused on overall metabolism of nascent HDL particles and revealed that LCAT (lecithin-cholesterol acyltransferase) plays only a minor role in the uptake and clearance of free cholesterol associated with nascent HDL.
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Cholesteryl Ester Transfer Protein
Human genetic studies have demonstrated associations between CETP variants and elevated HDL-C levels and lower cardiovascular disease (CVD) risk. 51 Reduced CETP (cholesteryl ester transfer protein) activity was thought to have antiatherogenic effects, as demonstrated by Zhang et al 52 who showed that rabbits with the CETP gene knocked out were protected against cholesterol diet-induced atherosclerosis.
However, 3 clinical trials of ASCVD outcomes testing CETP inhibitors have failed. 53 Important lessons extracted from these studies may help with overall understanding as to why certain inhibitors failed, or how the approach could be improved. 51, [53] [54] [55] For example, the CETP inhibitor anacetrapib was found to lower Lp(a) levels through a decrease in apo(a) production 56 and to raise apo AI and CETP levels through a decrease in their clearance rates, 57 which might contribute to its observed clinical benefit 58 beyond its ability to reduce LDL-C (low-density lipoprotein cholesterol). 59 Also, some individuals respond better to the CETP inhibitor dalcetrapib, 60 for which there is a genotype-dependent effect on ASCVD risk reduction, inflammation, and CEC, associated with particular genotypes of rs1967309, an SNP in the ADCY9 gene.
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Shingosine-1-Phosphate and Apo M S1P (sphingosine-1-phosphate) is a lipid mediator with vasoprotective properties, primarily carried by HDL through its interaction with apo M. [62] [63] [64] Protective qualities of HDL being attributed to the S1P/apo M complex include its endothelial anti-inflammatory features, 65 which some groups have examined. In a transgenic mouse model, CETP regulated the distribution of S1P and apo M between HDL particles and apo B-rich particles, but did not regulate S1P and apo M levels. 66 Another group examined levels of S1P and apo M in 89 patients with type 1 diabetes mellitus and 42 healthy controls. 67 Although there were no differences in S1P or apo M levels between cases and controls, the authors noticed that S1P/apo M complexes were more prevalent on light HDL particles, which corresponded to an increase in dysfunctional HDL particles in type 1 diabetes mellitus. 67 In another study, patients with metabolic syndrome and low HDL-C were found to lack S1P, 68 which seemed to be associated with the inability of HDL to protect against atherosclerosis. 68 Indeed, Denimal et al 68 determined that enriching HDL with S1P restored its functionality. Finally, in patients with diabetes mellitus, glycation was determined to be a mechanism that decreased S1P. 69 Again, HDL lacking S1P was compromised with respect to indices of vascular protection, but this capacity was recovered once HDL was enriched with S1P.
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HDL and Renal Function
Interest in the relationship between lipoproteins and kidney function, and in particular, the role of HDL, has intensified recently. Renal function is impaired in certain rare conditions of HDL depletion, such as LCAT deficiency. 70 Total cholesterol levels are associated with deterioration in renal function. 71 Serum lipids are associated with variation in sodium levels within the normal range. 72, 73 Specific apo constituents of HDL have independent associations with changes in renal function. 74 Apo LI in particular has emerged as a central player in this relationship. 75, 76 Mendelian randomization evaluates causal relationships between biomarkers and clinical end points. 77 Coassin et al 78 used Mendelian randomization focusing on 68 SNPs associated with HDL-C levels and estimated glomerular filtration rate as a measure of kidney function. Their findings suggested that there was no causal relationship between HDL-C and renal function. 78 In contrast, another Mendelian randomization study showed that genetically based increased HDL-C was causally associated with improved renal function. 79 More research is clearly needed in this area.
MicroRNAs and Lipoproteins
Early studies of microRNAs (miRNAs) focused on lipoprotein metabolism, and this area of research continues. 11, 80, 81 Canfrán-Duque et al 82 review the roles miRNAs play at various stages of reverse cholesterol transport. Ouimet et al 83 found a novel gene-targeted by miR-33 and miR-27b-that is involved in cholesterol trafficking and is also correlated with HDL-C levels. OSBPL6, encoding ORP6 (oxysterolbinding protein-related protein 6), is an LXR-responsive gene that is upregulated when cholesterol levels are elevated in mice and nonhuman primates. A decrease in ORP6 resulted in aberrant endosomal clustering, free cholesterol accumulation, and a decrease in cholesterol esterification, whereas an increase in ORP6 increased cholesterol trafficking and efflux in both hepatocytes and macrophages. 83 As well, an increase in hepatic OSBPL6 expression was correlated with an increase in HDL-C levels in 200 healthy individuals.
In a study focused on apo B-containing lipoproteins, miRNA-548p was shown to interact with 2 specific sites in APOB, which led to a decrease in apo B secretion. 84 Further, in the presence of miRNA-548p, there was a marked decrease in HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase) and ACSL4 (acyl-CoA synthetase long-chain family member 4), highlighting additional targets of this miRNA. 
Lipoprotein(a)
Elevated plasma levels of Lp(a) are an independent, causal risk factor for CVD 85 ; however, precise Lp(a)-level thresholds across populations are poorly defined. [86] [87] [88] In >500 000 American individuals, Varvel et al 89 established distributions and percentile thresholds of Lp(a) levels, which aligned closely with those reported from the Copenhagen General Population Study and the Copenhagen City Heart Study. Furthermore, Cao et al 90 studied 4678 individuals from the MESA cohort to establish Lp(a) thresholds in white, black, Hispanic, and Chinese individuals. At identical biochemical thresholds, there were differences in prevalence of calcific aortic valve disease between groups, indicating that different Lp(a) thresholds are required for different ethnicities to improve accuracy when assessing risk for CVD. 90 Genome-wide association studies have identified many SNPs associated with Lp(a) levels, but those studies are typically performed in European-based cohorts. Wang et al 91 sought to identify whether some SNP associations are seen in a Chinese Han population. They identified that only rs3088442-located in the SLC22A3-LPLAL2-LPA gene cluster-remained significantly associated with levels of Lp(a). They also found that rs3088442 was associated with severity of CAD in this population. Beyond genetic variants identified through genome-wide association studies, apo M has been a well-established lipoprotein component with a role in particle clearance. Moriarty et al 92 showed a relationship between APOE genotypes and Lp(a) levels; competition for receptors between Lp(a) and apo E may affect circulating Lp(a) as apo E isoforms are known to have varying affinities for receptors.
Several studies have evaluated Lp(a) associations with ASCVD risk in certain patient groups. For example, Enkhmaa et al 93 investigated the link between Lp(a) levels and CVD in women affected and unaffected by HIV; they found no significant association between prevalence of small apo A isoforms and high Lp(a) levels. In contrast, in a study of 3939 individuals with chronic kidney disease, Bajaj et al 94 reported a positive, independent correlation between Lp(a) levels and risk of both myocardial infarction and death.
In Germany, lipoprotein apheresis 95 has been available for individuals with Lp(a) hyperlipoproteinemia to potentially reduce risk of ASCVD. A 5-year follow-up in 154 individuals with elevated Lp(a) and progressive CVD undergoing apheresis has revealed that it has been successful in preventing further cardiovascular events. 96 In addition, over 95% of their cohort expressed a small form of apo A, which is 4-fold higher than what is expected in a general population. Similarly, the prevalence of rs3798220 and rs10455872 was increased compared with other individuals of a similar ethnicity with CVD.
Apo B-Containing Lipoproteins
Retention of apo B-containing lipoproteins is a central feature of atherogenesis, 97 and circulating apo B levels are emerging as a preferred predictor of atherosclerosis risk. 98 Zhang et al 99 identified a novel role in VLDL (very-low-density lipoprotein) metabolism for the AUP1 (ancient ubiquitous protein 1). This protein, localized to lipid droplets, was found to regulate VLDL particle secretion. 99 Once blocked, significant increase in secretion of VLDL particles was noted in HepG2 (hepatoma G2) cells. 99 In addition, these treated cells produced larger-sized lipid droplets. 99 Last, a direct effect was observed on apo B 100 , changing its ubiquitination, decreasing intracellular degradation, and increasing its secretion. 99 These interactions identified for AUP1 render it an interesting target for therapeutic development. 100 Given the causal role of LDL in atherosclerosis, 101 novel mechanisms to regulate LDL levels are of interest. Akkermansia muciniphila, a bacterium that degrades mucin, has been found to attenuate hyperlipidemia in mice once it colonizes the gut. 102 Data from Shen et al 102 suggest that apo B-containing lipoprotein levels are reduced because of increased expression of the LDLR (LDL receptor) and apo E after bacterial colonization in the gastrointestinal tract.
Immunosuppression with cyclosporine is associated with development of dyslipidemia and increased ASCVD risk. 103 In Ldlr-null and wild-type C57BL/6 mice, Kockx et al 104 showed that cyclosporine does not lead to hyperlipidemia via direct effects on the LDLR, although LDLR deficiency plays an enabling role. The complex dyslipidemia is because of abnormal lipoprotein clearance, decreased LPL (lipoprotein lipase) activity, and increased levels of apo CIII and abnormal PCSK9 (proprotein convertase subtilisin/kexin 9) activity. 104 In contrast, in ApoE-null mice subjected to elastase perfusion or angiotensin II infusion to induce aneurysm, and immunosuppressed with a monoclonal anti-CD20 antibody, there was significant depletion of B1 and B2 cells, and a striking suppression of aortic aneurysm progression, with minimal effect on the lipid profile.
105
LDL and Plaque Biology
Smooth muscle cells in atherosclerotic plaques express NG2 (neural/glial antigen 2) proteoglycan, whose genetic ablation in animal models is associated with hyperlipidemia and obesity. 106 She et al 107 investigated the impact of NG2 ablation on atherosclerosis in ApoE-null mice and found a 30% decrease in plaque development, despite worsened obesity and dyslipidemia. They further showed that NG2-positive smooth muscle cells sequestered LDL to enhance foam cell formation. 107 Thus, reduced smooth muscle cell-dependent LDL retention and foam cell formation offset the background of obesity and hyperlipidemia, suggesting that target inhibition of plaque NG2 could be a new approach to treat atherosclerosis. 107 Plaques also contain modified LDL particles. 108 , 109 Chellan et al 110 showed that in vitro, enzyme-modified nonoxidized LDL induces smooth muscle cell transformation. Enzymemodified nonoxidized LDL-C entered the cell via a calciumdependent macropinocytosis, a pathway that could explain the unexpected atherogenicity of certain calcium channel blockers. 110 Another study indirectly examined LDL modification; bilirubin is a product of heme degradation and a potent antioxidant that may protect LDL from oxidation. 111 Amor et al 111 showed that total serum bilirubin had an inverse association with carotid plaque burden in dyslipidemic patients.
Lipoproteins and Atherosclerosis Regression
Reducing apo B-containing lipoproteins causes plaque regression in numerous in vitro and in vivo model systems. 112 Subsets of particular cell types within plaques represent opportunities for intervention. 113, 114 Marcovecchio et al 115 investigated a subset of monocytes called nonclassical monocytes, which maintain the vasculature and protect the host from infections. In mice, nonclassical monocyte patrolling behavior was 4-fold increased on a Western diet, indicating induction of atheroprotective activity. 115 However, the protection was lost when the receptor CD36 adaptor protein , DAP12 (DNAX activating protein of 12 kDa), was absent. 115 This is a novel avenue for development of potential new therapeutics. e189
Bempedoic acid inhibits ATP citrate lyase, which produces acetyl coenzyme A for de novo synthesis of fatty acids and cholesterol. 116 Samsoondar et al 117 studied bempedoic acid in a mouse model of diet-induced metabolic dysregulation and found that it normalizes dyslipidemia, fatty liver, obesity, hyperglycemia, and hyperinsulinemia. They also found a 44% reduction in atherosclerotic lesion size. 117 This group reported comparable findings in a bempedoic acid-treated hyperlipidemia pig model. 118 Clinical trials of ASCVD outcomes with this agent are underway.
The lipoprotein-responsive PVRL2 gene, encoding poliovirus receptor-related 2, is located on chromosome 19q13.2, close to the APOE-C1-C2-C4 gene cluster that has been associated with both plasma lipoproteins and ASCVD risk.
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Pvrl2 expression in prelesion aortic endothelium was strongly induced by oxidized LDL. 120 In Pvrl2-null mice on an atherosclerosis-prone hyperlipidemia background, Rossignoli et al 121 found reduced lesion size, more stable plaques, and reduced transendothelial leukocyte migration. Because PVRL2 (poliovirus receptor-related 2) is primarily expressed in vascular endothelium, it is potentially targetable.
Remnant lipoproteins predict ASCVD risk and are causal factors in atherogenesis. 122 Bernelot Moens et al 123 investigated remnant cholesterol (defined as triglyceride-rich lipoproteins enriched in cholesterol) in patients with familial dysbetalipoproteinemia and demonstrated that they have lipid accumulation in monocytes, increased arterial wall inflammation, and increased metabolic activity in the bone marrow compared with healthy controls. In addition, in vitro studies demonstrated that hematopoietic stem and progenitor cells, when stimulated with remnant cholesterol, switch their metabolic program toward intracellular lipid storage. 123 Nine clinical trials (N=4957) were pooled to follow non-HDL-C and triglyceride levels in patients considered to have optimal LDL-C levels with statin treatment. 124 The study demonstrated that non-HDL-C rather than LDL-C was more closely associated with coronary atheroma progression and that triglyceride levels >200 mg/dL (>2.3 mmol/L) predict plaque progression. 124 This study emphasized the critical role of non-HDL lipoproteins in atherogenesis.
Lipoproteins and Autoantibodies
Atherosclerotic plaque formation activates an immune response from which autoantibodies (IgG and IgM) can be measured. 80, 125, 126 Prasad et al 127 investigated autoantibodies produced against oxidized LDL and apo B 100 complexes in the context of major ASCVD events and ethnic background. Presence of IgG malondialdehyde-modified LDL was associated across all ethnic groups with new major adverse ASCVD events (hazard ratio [HR], 1.76; P=0.009). 127 In addition, the effect of IgG was predominantly seen in black subjects (HR, 2.52; P=0.002). 127 IgG presence correlates with the highest ASCVD risk. 127 This study not only highlights known inflammation in atherogenic processes but also ethnicity-related differences. In contrast, high levels of autoantibodies against apo B 100 -specific peptides (IgM for p45 and IgG for p210) were associated with lower ASCVD events rates (HR, 0.72; P=0.017 and HR, 0.73; P=0.029, respectively). 128 Moreover, individuals with high IgG were protected from coronary plaques (HR, 0.81; P=0.008). 128 The studies by Prasad et al 127 and Björkbacka et al 128 were retrospective and prospective, respectively, using similar lab methods; both had large sample sizes (>3000 individuals) and long follow-up periods (>10 years). Further studies are needed to elucidate the role of autoantibodies against lipoproteins.
Anti-apo AI IgG antibodies were recently studied in the context of CAD risk prediction. 129 In >5220 individuals, Antiochos et al 129 found that individuals with anti-apo AI IgG had significantly more nonfatal CAD events compared with individuals without the antibody, at 3.6% and 2.3%, respectively. The HRs of anti-apo AI IgG for total and nonfatal CAD were 1.36 (P=0.105) and 1.53 (P=0.034), respectively. Further, they found that the strength of this relationship depended on the genotype of rs2569190, a functional polymorphism in CD14; anti-apo AI IgG participates in activating CD14-related pathways in the inflammatory response.
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Lessons From Human and Animal Hypercholesterolemia
Two of the most useful, time-tested animal models of atherosclerosis-Ldlr −/− and Apoe −/− mice-involve targeted disruptions in lipoprotein metabolic pathways; differences between these genetic backgrounds were reviewed by Getz and Reardon. 130 The utility of these models is emphasized by the number of times they have been reported in studies of diverse aspects of vascular biology and atherosclerosis. 115, We continue to learn how hypercholesterolemia propels atherogenesis in nonrodent model systems. For instance, Wang et al 162 found in transgenic rabbits that overexpressed LIPG, encoding endothelial lipase, were protected from developing diet-induced hypercholesterolemia and had a 52% reduction in atherosclerotic plaque development versus wildtype rabbits. Even in traditional rodent models, we continue to uncover novel ways in which hypercholesterolemia can be affected. Trenteseaux et al 163 investigated the offspring of female ApoE-null mice with hypercholesterolemia and found that female offspring decreased hepatic Scarb1 and Cyp7a1, but increased Nr1h4 and Fmo3 gene expression, trimethylamine-N-oxide levels, and aortic root lesions. They suggested that the findings could be explained by epigenetic alterations such as DNA methylation. 163 Patients with FH have long yielded insights into lipoprotein metabolism and atherosclerosis over the decades. [164] [165] [166] [167] [168] The genetics of FH are complex 169 ; diagnosis and treatment remain suboptimal. 170 In China, Li et al 171 screened for FH in a cohort of patients undergoing coronary angiography (N=8050). Using the Dutch Lipid Clinic Network criteria, they found that 3.5% of patients had definite or probable FH. 171 Women with FH were less likely to have experienced premature CAD compared with men with FH (70.6% versus 82.7%, P<0.001). 171 Molecular analysis revealed that half of the individuals (N=115, 46.9%) had a risk variant identified in the LDLR, APOB, and PCSK9 genes. 171 Treatment was suboptimal, even among patients with probably or definite FH patients: ≈27% of patients received either no treatment or e190
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low-intensity statin treatment, and no patient reached a target LDL-C level <100 mg/dL (<2.6 mmol/L). 171 Genetic understanding of FH has greatly expanded with next-generation sequencing. [172] [173] [174] [175] In patients with suspected heterozygous FH (LDL-C >194 mg/dL or >5 mmol/L), 47.3% had a monogenic cause, whereas 6.4% had large-scale copy-number variations and an additional 13.4% had high polygenic risk scores. 176 Thus, 67.1% of patients with heterozygous FH had a known genetic cause. 176 Among patients with LDL-C >8.0 mmol/L, 92% had an identified genetic cause of their disease (mainly monogenic mutations). 176 Molecular diagnosis of FH depends on simultaneous screening for monogenic mutations (including large-scale copynumber variations), 177 together with evaluation of polygenic risk burden. 178 Patient registries for FH allow collection of data on prognosis, clinical course, and outcomes, which can be hypothesis generating for basic science studies.
179-181 SAFEHEART (Spanish Familial Hypercholesterolemia Cohort Study) is an established national FH registry from Spain. 182 The study has to date recruited 4132 subjects of whom 3745 were ≥18 years and 2752 had molecularly diagnosed FH. A personal and family history of ASCVD was about 4× as prevalent in patients with FH as were CAD-related manifestations and peripheral artery disease, but not cerebrovascular events. Age, body mass index, type 2 diabetes mellitus, high blood pressure, tobacco use, and Lp(a) >50 mg/dL were each associated with ASCVD.
Ezetimibe: New Features of a Useful Medication
Ezetimibe, a nonstatin cholesterol-lowering medication 183 that is underused, 184 improves ASCVD outcomes when added to statins in patients who have not reached their LDL-C target. Ezetimibe primarily functions as a cholesterol absorption inhibitor that blocks NPC1L1 (Niemann Pick C1 like protein 1), 185 with other potential mechanisms of action to be elucidated. Lin et al 186 tested effects of ezetimibe on reverse cholesterol transport in 24 healthy subjects using validated cholesterol turnover methodology. They found ezetimibe reduced intestinal cholesterol absorption and circulating LDL-C and increased fecal cholesterol excretion, which is a distal biomarker of reverse cholesterol transport. 186 Ezetimibe also had a positive effect on coronary endothelial function, as seen in a multicenter, prospective, randomized involving 260 patients with CAD who received either statin monotherapy or statin plus ezetimibe. 187 Patients on combination treatment had improved prognoses, improved endothelial dysfunction, and decreased oxysterol levels. 187 But in a study of patients with metabolic syndrome, there was no difference in endothelial function whether the patients were on a statin alone or statin plus ezetimibe. 188 More work is needed to define possible pleiotropic effects of ezetimibe.
Diabetes Mellitus, Obesity, and Insulin Resistance
Type 2 diabetes mellitus is associated with multiple lipoprotein abnormalities, including hypertriglyceridemia, elevated small dense LDL particles, and reduced HDL that act together to increase ASCVD risk. [189] [190] [191] LPL plays a central mechanistic role in these multiple abnormalities. For instance, Chiu et al 192 reported in a rat model that cardiomyocytes, in response to low glucose accessibility associated with insulin resistance, switch to exclusively using LPL-mediated triglyceride hydrolysis for energy. They noted an increase in coronary lumen LPL and a related increase in its transporter in moderately severe diabetes mellitus. 192 The trigger to this increase represents the reaction of ECs to a hyperglycemic environment and the subsequent stimulation for myocytes to release growth factor, which is the final culprit to the switch. Interestingly, this adaptation ceased in long-term or more severe diabetic models. 192 Insulin-resistant patients have multiple disturbances of lipoprotein production and secretion. 190 Three studies investigated from different portals of entry-gut, intranasal, and intravenous-show how lipoprotein production responds to insulin or glucose changes. Khound et al 193 investigated the effect of a subdiaphragmatic vagotomy, a procedure intended to control weight gain, on murine hepatic lipid production. The procedure was associated with (1) elevated GLP-1 (glucagon-like peptide-1), (2) significant reductions in mRNA and protein expression of SREBP-1c, stearoyl-CoA desaturase-1, and fatty acid synthase, and (3) enhanced hepatic insulin sensitivity. In vitro, treating mouse primary hepatocytes with the GLP-1 receptor agonist, exendin-4, for 48 hours inhibited free fatty acid, whereas palmitic acid treatment induced de novo lipid synthesis and VLDL secretion. 193 Thus, Khound et al 193 found an incretin-centric gut-liver regulatory circuit that modulates hepatic lipogenesis and insulin sensitivity. In 9 healthy men, Xiao et al 194 investigated intranasal insulin given at a dose known to suppress both cerebrospinal fluid insulin concentration and hepatic glucose production. In a parallel study arm, insulin was given at an equipotent dose intravenously. Using stable isotope markers and multicompartmental modeling, they found no significant effects of intranasal insulin versus placebo on triglyceride-rich lipoprotein apo B 100 or B 48 concentrations, fractional catabolic rates, or production rates. 194 The same group 195 showed how a shortterm intravenous infusion of glucose stimulates intestinal lipoproteins, indicating a mechanism whereby hyperglycemia may be the primary driver of the lipid abnormalities at the intestinal level. 195 Thus, insulin's complex effects on plasma lipoproteins depend on the target tissue, route of administration, chronicity of administration, availability of intact incretin circuitry, and metabolic context, such as dietary fat intake and ambient glucose levels.
Adipocytes are central to insulin resistance. Rydén and Arner 196 studied >1000 individuals and found that elevated rates of spontaneous lipolysis and decreased rates of insulininhibited lipolysis were associated with decreased HDL-C and increased triglyceride levels. Further, lipolysis determined ≈14% of variation in HDL-C and triglyceride levels. Another study examined LRP1 (LDLR-related protein 1) in adipocytes, where its role is less well understood than in liver. 197 Dysfunctional LRP1 in hepatocytes and macrophages is associated with increased atherosclerosis by diet-induced hyperlipidemia and inflammation, respectively. 202 transfected male angiotensin II-infused C57BL/6 mice with an adenovirus containing the cholesterolraising gain-of-function p.D377Y variant of PCSK9 to provide an alternative model system to induced mutant Ldlr-null or ApoE-null mice. They found that mice with the introduced mutation had hypercholesterolemia and developed angiotensin II-induced abdominal aortic aneurysm, comparable to induced mutant mice. 202 To explore new therapeutic PCSK9-based approaches, Chadwick et al 203 used CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/clustered regularly interspaced short palindromic repeat-associated 9) to introduce the p.Q302X nonsense mutation into Pcsk9 in the liver of adult mice. Treated mice had lower circulating PCSK9 protein and plasma cholesterol. 203 The data demonstrated the potential of CRISPR/Cas9 to modify somatic tissues in adult mammals with no apparent safety concerns.
A naturally occurring PCSK9 variant, p.R46L, is associated with reduced LDL-C and ASCVD events. 204 Verbeek et al 205 showed that patients who carried this mutation had reduced plasma concentrations of VLDL and LDL-C, and reduced Lp(a), secretory phospholipase A2, and lipoprotein-associated phospholipase A2 activity compared with controls.
PCSK9 inhibitors are partially effective in reducing LDL-C in patients with homozygous FH who have bi-allelic LDLR mutations with at least some residual receptor function encoded by 1 mutant allele. 206 An even rarer form of homozygous FH called autosomal recessive hypercholesterolemia results from bi-allelic mutations in the LDLRAP1 gene, encoding LDLR-associated protein type 1. 207 Thedrez et al 208 reported, using in vitro models, that alirocumab treatment versus recombinant PCSK9 had opposite effects on LDLR expression and LDL uptake by lymphocytes from both autosomal recessive hypercholesterolemia and control groups; cells from the patients with autosomal recessive hypercholesterolemia showed somewhat attenuated responses as observed clinically.
209
Insights From Rare Disorders of Lipoprotein Metabolism
Potential molecular targets are sought using clues from families with rare genetic disorders. One such condition is chylomicron retention disease because of bi-allelic defects in the SAR1B gene, 210 causing defective chylomicron secretion and intestinal fat engorgement. Sané et al 211 silenced the SAR1B gene in human Caco-2/15 intestinal cells using zinc-finger nuclease and showed reductions of 35% to 50% in secretion of triglycerides, apo B 48 , and chylomicrons. However, a double knockout of both SAR1B and SAR1A completely inhibited their secretion, thus recapitulating the phenotype. 211 It may thus be possible to develop an intervention that will partially reduce secretion of triglyceride-rich lipoproteins without the adverse gastrointestinal effects that are associated with complete suppression.
CRISPR/Cas9 gene editing can efficiently provide model systems to study human disease, both by inducing mutations for experiments and potentially repairing mutations therapeutically. Successes have been observed in CRISPR/Cas9 experiments involving stem cell-derived macrophages. For example, Gupta et al 212 created isogenic, human pluripotent stem cell-derived macrophages with and without ABCA1. This method will be useful for studying naturally occurring ABCA1 mutations in patients with Tangier disease. Similarly, Zhang 213 created human induced pluripotent stem cell-derived macrophages to better understand the role of LIPA, the causative gene for lysosomal acid lipase deficiency and Wolman disease. In a LIPA −/− knockout of their genetically engineered macrophages, the authors explored the role of lysosomal acid lipase in cholesterol efflux and gene expression. 214 They found that lysosomal hydrolysis of cholesterol esters was abolished, function and expression of ABCA1 was not altered, degradation of apo B was not affected, and gene expression of inflammatory genes was not altered.
Gene expression profiling on EC interaction with lipoproteins in vivo demonstrated that lipoproteins function as a signaling molecule to ECs. 215 Indeed, low levels of circulating lipoproteins signal ECs to upregulate the enzyme autotaxin which in turn activate angiogenesis and sprouting. 215 The opposite is seen in hyperlipidemia states. This is a novel signaling role for lipoproteins and can be a potential area of exploration in the understanding of vascular pathologies.
Conclusions
Articles on lipoproteins continue to populate a significant number of ATVB journal pages. Studies used a wide range of in vitro and in vivo tools and model systems to define mechanisms and targets that portend improvements in understanding of lipoprotein metabolism. Recurring themes include cellular and molecular studies, functional validations, miRNAs, translational studies, gene editing, and the genetic basis of dyslipidemias. HDL biology remains popular among contributors, readers, and editors. Emerging trends include evaluation of lipoproteins in disease states such as renal disease, diabetes mellitus, and inflammatory and immune disorders. Finally, combining findings across a wide range of experiments and then rapidly translating them into the clinical realm will undoubtedly continue. Individually and in aggregate, the science of lipoproteins reported in ATVB provides a gateway to future research. 
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